Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 12

Non-invasive ventilation with intelligent volume-assured pressure support versus pressure-controlled ventilation: effects on the respiratory event rate and sleep quality in COPD with chronic hypercapnia

Authors Nilius G, Katamadze N, Domanski U, Schroeder M, Franke KJ

Received 7 November 2016

Accepted for publication 6 February 2017

Published 30 March 2017 Volume 2017:12 Pages 1039—1045

DOI https://doi.org/10.2147/COPD.S126970

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Charles Downs

Peer reviewer comments 3

Editor who approved publication: Dr Richard Russell

Georg Nilius,1,2 Nato Katamadze,1,2 Ulrike Domanski,1 Maik Schroeder,1 Karl-Josef Franke1,2

1HELIOS Klinik Hagen-Ambrock, 2Internal Medicine I, Witten/Herdecke University, Witten, Germany

Background: COPD patients who develop chronic hypercapnic respiratory failure have a poor prognosis. Treatment of choice, especially the best form of ventilation, is not well known.
Objectives: This study compared the effects of pressure-controlled (spontaneous timed [ST]) non-invasive ventilation (NIV) and NIV with intelligent volume-assured pressure support (IVAPS) in chronic hypercapnic COPD patients regarding the effects on alveolar ventilation, adverse patient/ventilator interactions and sleep quality.
Methods: This prospective, single-center, crossover study randomized patients to one night of NIV using ST then one night with the IVAPS function activated, or vice versa. Patients were monitored using polysomnography (PSG) and transcutaneous carbon dioxide pressure (PtcCO2) measurement. Patients rated their subjective experience (total score, 0–45; lower scores indicate better acceptability).
Results: Fourteen patients were included (4 females, age 59.4±8.9 years). The total number of respiratory events was low, and similar under pressure-controlled (5.4±6.7) and IVAPS (8.3±10.2) conditions (P=0.064). There were also no clinically relevant differences in PtcCO2 between pressure-controlled and IVAPS NIV (52.9±6.2 versus 49.1±6.4 mmHg). Respiratory rate was lower under IVAPS overall; between-group differences reached statistical significance during wakefulness and non-rapid eye movement sleep. Ventilation pressures were 2.6 cmH2O higher under IVAPS versus pressure-controlled ventilation, resulting in a 20.1 mL increase in breathing volume. Sleep efficiency was slightly higher under pressure-controlled ventilation versus IVAPS. Respiratory arousals were uncommon (24.4/h [pressure-controlled] versus 25.4/h [IVAPS]). Overall patient assessment scores were similar, although there was a trend toward less discomfort during IVAPS.
Conclusion: Our results show that IVAPS NIV allows application of higher nocturnal ventilation pressures versus ST without affecting sleep quality or inducing ventilation-associated events.

Keywords: NIV, IVAPS, COPD, hypercapnia

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

A randomized controlled trial to validate the Alice PDX ambulatory device

Nilius G, Domanski U, Schroeder M, Franke KJ, Hogrebe A, Margarit L, Stoica M, d'Ortho MP

Nature and Science of Sleep 2017, 9:171-180

Published Date: 6 June 2017

Telemonitoring of home exercise cycle training in patients with COPD

Franke KJ, Domanski U, Schroeder M, Jansen V, Artmann F, Weber U, Ettler R, Nilius G

International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:2821-2829

Published Date: 11 November 2016